ASMI announces new Board members

30 November 2017

Return to Media Release Index

The Australian Self Medication Industry (ASMI) announced its new Board of Directors at its Annual General Meeting this week.

The election of three board directors was confirmed at the AGM.

Rob Barnes (Aspen), Andrew Jenkin (Pfizer) and Alan Oppenheim (Ego Pharmaceuticals) will be joining current board directors, Lindsay Forrest (Chairman), Doug Cunningham (J&JP) and Mark Sargent (Bayer).

Following the AGM, the incoming board appointed James Jones (Takeda) and Stephen Moodey (GSK) to fill two of the four casual vacancies.

The following office bearers were also appointed:

    Doug Cunningham, Vice Chair

    James Jones, Secretary

    Rob Barnes, Treasurer

 Lindsay Forrest extended his congratulations to the newly appointed directors.

The ASMI AGM also featured guest speaker Craig Woolford, Citigroup managing director and head of consumer sector research, who addressed members on 'Amazon and its Impact on the Australian Market'.